Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marta Zola

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Retinal Cases & Brief Reports|August 4, 2018
OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY IMAGING OF A CONGENITAL SIMPLE HAMARTOMA OF THE RETINAL PIGMENT EPITHELIUMMarta Zola, Aude Ambresin, Leonidas Zografos
Retina (Philadelphia, Pa.)|February 25, 2022
EVIDENCE AGAINST A CONTRALATERAL COATS PHENOTYPE BY OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHYAlejandra Daruich, Marta Zola, Martine Elalouf, et al.
Retina (Philadelphia, Pa.)|June 2, 2017
RISK FACTORS FOR RECURRENCES OF CENTRAL SEROUS CHORIORETINOPATHYAlexandre Matet, Alejandra Daruich, Marta Zola, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|August 12, 2017
Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with AfliberceptParmis Parvin, Marta Zola, Ali Dirani, et al.
The British Journal of Ophthalmology|September 1, 2018
Factors influencing macular atrophy growth rates in neovascular age-related macular degeneration treated with ranibizumab or aflibercept according to an observe-and-plan regimenIrmela Mantel, Marta Zola, Sophie De Massougnes, et al.
The British Journal of Ophthalmology|July 22, 2018
Antidepressant medication and ocular factors in association with the need for anti-VEGF retreatment in neovascular age-related macular degenerationIrmela Mantel, Marta Zola, Olivier Mir, et al.
The British Journal of Ophthalmology|October 26, 2018
Two-year follow-up of mineralocorticoid receptor antagonists for chronic central serous chorioretinopathyMarta Zola, Alejandra Daruich, Alexandre Matet, et al.
Acta Ophthalmologica|April 16, 2018
Evolution of fundus autofluorescence patterns over time in patients with chronic central serous chorioretinopathyMarta Zola, Irini Chatziralli, Deepthy Menon, et al.
Expert Opinion on Investigational Drugs|August 31, 2023
Retinal stroke: research models, targets and experimental drugsAlejandra Daruich, Matthieu P Robert, Marta Zola, et al.
Eye (London, England)|January 26, 2024
Short-term response to anti-VEGF as indicator of visual prognosis in refractory age-related macular degenerationAnthony Gigon, Antonio Iskandar, Sophie Kasser, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Retinal Cases & Brief Reports|August 4, 2018
OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY IMAGING OF A CONGENITAL SIMPLE HAMARTOMA OF THE RETINAL PIGMENT EPITHELIUMMarta Zola, Aude Ambresin, Leonidas Zografos
Retina (Philadelphia, Pa.)|February 25, 2022
EVIDENCE AGAINST A CONTRALATERAL COATS PHENOTYPE BY OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHYAlejandra Daruich, Marta Zola, Martine Elalouf, et al.
Retina (Philadelphia, Pa.)|June 2, 2017
RISK FACTORS FOR RECURRENCES OF CENTRAL SEROUS CHORIORETINOPATHYAlexandre Matet, Alejandra Daruich, Marta Zola, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|August 12, 2017
Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with AfliberceptParmis Parvin, Marta Zola, Ali Dirani, et al.
The British Journal of Ophthalmology|September 1, 2018
Factors influencing macular atrophy growth rates in neovascular age-related macular degeneration treated with ranibizumab or aflibercept according to an observe-and-plan regimenIrmela Mantel, Marta Zola, Sophie De Massougnes, et al.
The British Journal of Ophthalmology|July 22, 2018
Antidepressant medication and ocular factors in association with the need for anti-VEGF retreatment in neovascular age-related macular degenerationIrmela Mantel, Marta Zola, Olivier Mir, et al.
The British Journal of Ophthalmology|October 26, 2018
Two-year follow-up of mineralocorticoid receptor antagonists for chronic central serous chorioretinopathyMarta Zola, Alejandra Daruich, Alexandre Matet, et al.
Acta Ophthalmologica|April 16, 2018
Evolution of fundus autofluorescence patterns over time in patients with chronic central serous chorioretinopathyMarta Zola, Irini Chatziralli, Deepthy Menon, et al.
Expert Opinion on Investigational Drugs|August 31, 2023
Retinal stroke: research models, targets and experimental drugsAlejandra Daruich, Matthieu P Robert, Marta Zola, et al.
Eye (London, England)|January 26, 2024
Short-term response to anti-VEGF as indicator of visual prognosis in refractory age-related macular degenerationAnthony Gigon, Antonio Iskandar, Sophie Kasser, et al.
Pageof 3